👉 Over 7 million people live with kidney disease in the UK - yet it was barely mentioned in the Government’s 10-year health plan.
It’s time for action.
Sign our open letter to the Prime Minister calling for a national strategy for CKD and help build a better future for kidney patients: https://t.co/h1gnVPlf2x
@kidneycareuk, @Kidney_Research, @NKF_UK and @UKKidney are all on board. Are you?
#CKDStrategy
📣We're all set for our first-ever PKD Info & Support Day in Leicester this Sat, 28 June – and we can’t wait! 🎉
A packed agenda, expert clinicians, and the chance for our PKD families to meet new friends.
📍Next up: Exeter, 8 Nov – save the date! Make sure you’re signed up to receive our e-news so you never miss updates on upcoming in-person and online events>https://t.co/ggF7xVQdgf
Implementation and Evaluation of a Smartphone-Based Application for Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients:
A Prospective Feasibility Cohort Study and Collaborative Effort of Patients and the Peritoneal Dialysis Team
https://t.co/OgqI1FATz1
🟡💜It's World Kidney Day! 💜🟡
Today, we shine a light on the 7+ million people living with kidney disease, the incredible organ donors, families, and healthcare professionals who support them, and the countless others at risk but unaware.
👊Help raise awareness about the importance of our kidneys and stand with those facing kidney disease. Please share!
#KidneysMatter #WorldKidneyDay #ADPKD #ARPKD
📢 It's #WorldKidneyDay & it's time for EVERYONE to take their #BloodyAmazingKidneys more seriously!
We're dedicated to raising awareness of the #BloodyAmazing job our #Kidneys do everyday, & to help identify those most at risk of developing #CKD 👇 https://t.co/gXx2s4lb73
New Guidelines Set to Transform PKD Care!
The first-ever KDIGO guidelines for autosomal dominant polycystic kidney disease (ADPKD) are here.
Developed over a decade with input from healthcare professionals, researchers, and patient groups, including PKD Charity, they set a new standard for diagnosis, prognosis and treatment - ensuring patients receive the right care, at the right time.⏳
View and download guidelines: https://t.co/LU5yWbKfHg
📢Looking for guidance on how to best manage Polycystic Kidney Disease (PKD)?
Join us at our Leicester Information & Support Day, hosted by Kidney Specialist Dr Osasuyi Iyasere.
Attendance is free to patients, family members and healthcare professionals, including lunch and refreshments throughout the day!
Register 👉https://t.co/7WdlVOa3Ht
Individuals receiving hemodialysis are susceptible to QT interval–prolonging medication–related cardiac complications. This study found ondansetron initiation is associated with higher 10-day sudden cardiac death risk https://t.co/zXT5pGEOV4
@UNCKidney
📢New study finds 12-week cognitive & physical training program during HD sessions significantly improves cognitive function & mobility in patients. Integrated interventions show promise in mitigating functional declines & enhancing quality of life. 👟
🔗https://t.co/Q3AWGa8mVD
Inequities in access to #CKD treatment exist. Through advocacy efforts, awareness-raising activities, and strengthening health systems, we can make a real difference for people living with kidney disease.
https://t.co/5alA8GgJH4
#WorldKidneyDay#KidneyHealthforAll
Tolvaptan treatment is associated with altered mineral metabolism parameters and increased bone mineral density in ADPKD patients
👉https://t.co/5BJ1ALwo6i👈
Registration is now open for the @YAKidneyGroup annual residential weekend. This free event is for young people aged 18-30 who have a kidney condition: https://t.co/iwDxXXiAgu
📣 Guideline update 📣
The #Vascular Access for #Haemodialysis guideline is now available in an accessible style written by a multiprofessional team:
📖 https://t.co/gtVXmVuscR
🔹Variation in characteristics
🔹Importance of patient choice
🔹Individualised clinical approach
In all groups - response better with younger age, prior infection and more vaccines.
Triple immunosuppression in SOTs & anti-CD20 in autoimmune/cancer cohorts associated with non-response.
No abs = approx 1 in 5.
Correlation with infection/outcome - to follow soon.
📢 The new PKD App is now available to download! Ideal for the newly diagnosed/early stages of ADPKD, it offers:
✔️ Credible information & accredited health advice
✔️ Practical tips for everyday life
✔️ Links to trusted further information & support
More👉https://t.co/TnGUoZDHG0
Hot of the Press. Results from our latest trial.
Empagliflozin (originally a diabetes treatment) reduces risk of kidney disease progression (incl. dialysis) or cardiovascular death in pts with or without diabetes & regardless of level of kidney function
https://t.co/iGazwOeE2o